SuanFarma-Header SuanFarma-Header

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter Country
      filter News Type
        filter Company
          filter Product Type
            filter Deal Size

              Active Filter(s):

              refreshReset Filter
              refresh Reset Filter
              price-trend All Drugs in Dev.

              Product Type

              Companies

              DiCE Molecules

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              Post An Enquiry Post An Enquiry
              Flag United States
              Virtual Booth Virtual Booth

              Mediterranean Congress of Chemical

              Participation Not Confirmed

              Update your events

              DiCE Molecules Announces $60 Million Series C-1 Financing

              Lead Product(s): S011806

              Therapeutic Area: Dermatology Product Name: S011806

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: RA Capital Management

              Deal Size: $60.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing August 24, 2021

              Details:

              Proceeds of the financing are expected to be used to support advancement of the Company’s preclinical IL-17 antagonist, S011806 into clinical development, advancement of preclinical α4ß7 and αVß1/αVß6 integrin programs, pipeline expansion and other general corporate purposes.